about
Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseasesChimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.Evaluation of mucoadhesive PLGA microparticles for nasal immunization.Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responsesMutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.Health risks associated with inhaled nasal toxicants.Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.Immunological aspects of polymer microsphere vaccine delivery systems.Strategies for intranasal delivery of vaccinesOral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.Effect of Experimental Parameters on Alginate/Chitosan Microparticles for BCG Encapsulation.Different routes and doses influence protection in pigs immunised with the naturally attenuated African swine fever virus isolate OURT88/3Nasal-nanotechnology: revolution for efficient therapeutics delivery.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Development of chitosan-pullulan composite nanoparticles for nasal delivery of vaccines: optimisation and cellular studies.Adjuvant action of melittin following intranasal immunisation with tetanus and diphtheria toxoids.DNA vaccine expressing herpes simplex virus 1 glycoprotein C and D protects mice against herpes simplex keratitis.Strategies for vaccine delivery.BCG-loaded chitosan microparticles: interaction with macrophages and preliminary in vivo studies.Adjuvant synergy: the effects of nasal coadministration of adjuvants.
P2860
Q28087409-F2E9370C-BB46-49AC-ABE2-9E7C5549E5DFQ33640085-DBEC321A-0DEF-4719-A617-09CB32C88805Q33749489-6B1833D4-5CC3-44B8-9C44-4CB8E077E0F2Q33846577-127FAA2E-C363-4F3A-A777-6FF873272482Q34002672-22506691-81B3-4A8D-A41A-B6DDF3172A59Q34281120-2CD61D6E-E975-4964-BD0A-EA06EA73AC03Q34353473-C094F7D9-E538-4FD3-B823-1992D3D4D9A1Q35809248-C3E39327-E3E8-4373-944D-9F9ED94CC8B5Q36514771-4F35F517-1CF0-4224-BB14-9C8DE6D2E14DQ36640081-C432FF44-AC54-4766-9D48-92B8D0CB1E76Q36941463-E1BB26D3-6044-404D-BDD9-1413318B468DQ37594124-C3824E9B-BE8E-4E30-A803-793B258D7B05Q38217878-903AA8E7-B3CE-4ADE-A245-9710B74097CFQ38461061-0A31FEC0-065C-4BF4-890B-8D5384564E67Q38826782-B1402EC9-F901-4232-873A-7380BA765F54Q41462282-7B8D0830-C5E7-4E48-A2AD-90A3C7038F26Q45324169-0AA24E7B-F587-4476-8C21-E1D722A46662Q47326792-3F6647E9-0E8B-43E1-8CC8-96D2F6D56A56Q48318390-AF77FFFC-42E0-4B40-A34A-F719F87C880FQ51996299-E7129065-B0BB-4DFB-8FC0-F8D5E91A4A1E
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Nasal delivery of vaccines.
@en
type
label
Nasal delivery of vaccines.
@en
prefLabel
Nasal delivery of vaccines.
@en
P2860
P1476
Nasal delivery of vaccines.
@en
P2093
P2860
P304
P356
10.3109/10611869609015965
P577
1996-01-01T00:00:00Z